Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.
|
22504420 |
2012 |
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.
|
22504420 |
2012 |
Nodule
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Interestingly, rapamycin in rapamycin plus lipopolysaccharide (LPS)‑treated BMSCs significantly increased the gene expression levels of Sp7 transcription factor, runt related transcription factor 2, alkaline phosphatase (ALP) and collagen I (Col I), ALP activity, and calcium nodule at different time points in vitro, indicating that osteoblast differentiation occurs by rapamycin when BMSCs are exposed to LPS simultaneously.
|
28990080 |
2017 |
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Meta-analysis of gene-based genome-wide association studies of bone mineral density in Chinese and European subjects.
|
21927923 |
2012 |
Craniofacial Abnormalities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Mutations of the Sp7 gene in humans are associated with craniofacial anomalies and osteogenesis imperfecta.
|
29405385 |
2018 |
Osteogenesis Imperfecta
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the Sp7 gene in humans are associated with craniofacial anomalies and osteogenesis imperfecta.
|
29405385 |
2018 |
Bone Diseases
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.
|
18829486 |
2008 |
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
New sequence variants associated with bone mineral density.
|
19079262 |
2009 |
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
New sequence variants associated with bone mineral density.
|
19079262 |
2009 |
Osteogenesis imperfecta type IV (disorder)
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Nosology and classification of genetic skeletal disorders: 2010 revision.
|
21438135 |
2011 |
OSTEOGENESIS IMPERFECTA, TYPE XII
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel variant in Sp7/Osx associated with recessive osteogenesis imperfecta with bone fragility and hearing impairment.
|
29382611 |
2018 |
Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
Osteosarcoma of bone
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
Childhood Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation.
|
18838962 |
2008 |
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The results revealed that proliferation, apoptosis and the mRNA expression levels of RUNX2 and SP7 in MDS-MSCs did not significantly change following treatment with decitabine compared with control MDS-MSCs.
|
31611955 |
2019 |
Peripheral ossifying fibroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of Osterix protein in the pathogenesis of peripheral ossifying fibroma.
|
28678972 |
2017 |
Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Osteosarcoma of bone
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Childhood Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transfection of the osx gene into the mouse osteosarcoma cells inhibited tumor cell growth in vitro and in vivo and significantly reduced tumor incidence, tumor volume, and lung metastasis following intratibial injection.
|
15734992 |
2005 |
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |
Osteosarcoma of bone
|
0.030 |
Biomarker
|
disease |
BEFREE |
We used quantitative real-time polymerase chain reaction to evaluate the gene expression of MDM2, CXCR4, RANKL, RB1, and OSTERIX in 98 samples of osteosarcoma taken from 47 patients (74 metastases and 24 primary tumors) and 30 nonmalignant lung tissues surrounding osteosarcoma metastases.
|
23845465 |
2013 |